|
1
|
Fattovich G, Stroffolini T, Zagni I and
Donato F: Hepatocellular carcinoma in cirrhosis: incidence and risk
factors. Gastroenterology. 127:S35–S50. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rehermann B and Nascimbeni M: Immunology
of hepatitis B virus and hepatitis C virus infection. Nat Rev
Immunol. 5:215–229. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Colombo M: Hepatitis C virus and
hepatocellular carcinoma. Semin Liver Dis. 19:263–269. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Anzola M: Hepatocellular carcinoma: role
of hepatitis B and hepatitis C viruses proteins in
hepatocarcinogenesis. J Viral Hepat. 11:383–393. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kasprzak A and Adamek A: Role of hepatitis
C virus proteins (C, NS3, NS5A) in hepatic oncogenesis. Hepatol
Res. 38:1–26. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Alexia C, Fallot G, Lasfer M,
Schweizer-Groyer G and Groyer A: An evaluation of the role of
insulin-like growth factors (IGF) and of type-I IGF receptor
signalling in hepatocarcinogenesis and in the resistance of
hepatocellular cells against drug-induced apoptosis. Biochem
Pharmacol. 86:1003–1015. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kasprzak A and Adamek A: The insulin-like
growth factor (IGF) signaling axis and hepatitis C virus-associated
carcinogenesis (Review). Int J Oncol. 41:1919–1931. 2012.PubMed/NCBI
|
|
8
|
Daughday WH and Rotweien P: Insulin-like
growth factors I and II: peptide, messenger ribonucleic acid, and
gene structures, serum and tissue concentrations. Endocr Rev.
10:68–91. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zarilli R, Bruni CB and Riccio A: Multiple
levels of control of insulin-like growth factor gene expression.
Mol Cell Endocrinol. 101:R1–R14. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Juul A, Bang P, Hertel NT, et al: Serum
insulin-like growth factor-I in 1030 healthy children, adolescents,
and adults: relation to age, sex, stage of puberty, testicular
size, and body mass index. J Clin Endocrinol Metab. 78:744–752.
1994.PubMed/NCBI
|
|
11
|
Brabant G and Wallaschofski H: Normal
levels of serum IGF-I: determinants and validity of current
reference ranges. Pituitary. 10:129–133. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kostecka Y and Blahovec J: Insulin-like
growth factor binding proteins and their functions (minireview).
Endocr Regul. 33:90–94. 1999.PubMed/NCBI
|
|
13
|
Le Roith D, Bondy C, Yakar S, Liu JL and
Butler A: The somatomedin hypothesis: 2001. Endocr Rev. 22:53–74.
2001.
|
|
14
|
Elmlinger MW, Kühnel W, Weber MM and Ranke
MB: Reference ranges for two automated chemiluminescent assays for
serum insulin-like growth factor I (IGF-I) and IGF-binding protein
3 (IGFBP-3). Clin Chem Lab Med. 42:654–664. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yu H, Mistry J, Nicar MJ, Khosravi MJ,
Diamandis A, van Doorn J and Juul A: Insulin-like growth factors
(IGF-I, free IGF-I, and IGF-II) and insulin-like growth factor
binding proteins (IGFBP-2, IGFBP-3, IGFBP-6, and ALS) in blood
circulation. J Clin Lab Anal. 13:166–172. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Juul A, Dalgaard P, Blum WF, et al: Serum
levels of insulin-like growth factor (IGF)-binding protein-3
(IGFBP-3) in healthy infants, children, and adolescents: the
relation to IGF-I, IGF-II, IGFBP-1, IGFBP-2, age, sex, body mass
index, and pubertal maturation. J Clin Endocrinol Metab.
80:2534–2542. 1995.PubMed/NCBI
|
|
17
|
Mattsson A, Svensson D, Schuett B,
Osterziel KJ and Ranke MB: Multidimensional reference region for
IGF-I, IGFBP-2 and IGFBP-3 concentrations in serum healthy adults.
Growth Horm IGF Res. 18:506–516. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Raslan HM, Elhosary Y, Ezzat WM, Rasheed
EA and Rasheed MA: The potential role of insulin-like growth factor
1, insulin-like growth factor binding protein 3 and bone mineral
density in patients with chronic hepatitis C virus in Cairo, Egypt.
Trans R Soc Trop Med Hyg. 104:429–432. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Blum WF, Albertsson-Wikland K, Rosberg S
and Ranke MB: Serum levels of insulin-like growth factor I (IGF-I)
and IGF binding protein 3 reflect spontaneous growth hormone
secretion. J Clin Endocrinol Metab. 76:1610–1616. 1993.PubMed/NCBI
|
|
20
|
Wu JC, Daughaday WH, Lee SD, et al:
Radioimmunoassay of serum IGF-I and IGF-II in patients with chronic
liver diseases and hepatocellular carcinoma with or without
hypoglycemia. J Lab Clin Med. 112:589–594. 1988.PubMed/NCBI
|
|
21
|
Kratzsch J, Blum WF, Schenker E and Keller
E: Regulation of growth hormone (GH), insulin-like growth factor
(IGF) I, IGF binding proteins -1, -2, -3 and GH binding protein
during progression of liver cirrhosis. Exp Clin Endocrinol
Diabetes. 103:285–291. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Völzke H, Nauck M, Rettig R, Dörr M,
Higham C, Brabant G and Wallaschofski H: Association between
hepatic steatosis and serum IGF1 and IGFBP-3 levels in a
population-based sample. Eur J Endocrinol. 161:705–713.
2009.PubMed/NCBI
|
|
23
|
Rehem RN and El-Shikh WM: Serum IGF-1,
IGF-2 and IGFBP-3 as a parameters in the assessment of liver
dysfunction in patients with hepatic cirrhosis and in the diagnosis
of hepatocellular carcinoma. Hepatogastroenterology. 58:949–954.
2011.PubMed/NCBI
|
|
24
|
Vyzantiadis T, Theodoridou S, Giouleme O,
Harsoulis P, Evgenidis N and Vyzantiadis A: Serum concentrations of
insulin-like growth factor-I (IGF-I) in patients with liver
cirrhosis. Hepatogastroenterology. 50:814–816. 2003.PubMed/NCBI
|
|
25
|
Lorenzo-Zúñiga V, Bartolí R, Masnou H,
Montoliu S, Morillas RM and Planas R: Serum concentration of
insulin-like growth factor-I (igf-I) as a marker of liver fibrosis
in patients with chronic hepatitis C. Dig Dis Sci. 52:3245–3250.
2007.PubMed/NCBI
|
|
26
|
Nikolić JA, Todorović V, Bozić M, et al:
Serum insulin-like growth factor (IGF)-II is more closely
associated with liver disfunction than is IGF-I in patients with
cirrhosis. Clin Chim Acta. 294:169–177. 2000.PubMed/NCBI
|
|
27
|
Stuver SO, Kuper H, Tzonou A, Lagiou P,
Spanos E, Hsieh CC, Mantzoros C and Trichopoulos D: Insulin-like
growth factor 1 in hepatocellular carcinoma and metastatic liver
cancer in men. Int J Cancer. 87:118–121. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wu YL, Ye J, Zhang S, Zhong J and Xi RP:
Clinical significance of serum IGF-I, IGF-II and IGFBP-3 in liver
cirrhosis. World J Gastroenterol. 10:2740–2743. 2004.PubMed/NCBI
|
|
29
|
Mazziotti G, Sorvillo F, Morisco F, et al:
Serum insulin-like growth factor I evaluation as a useful tool for
predicting the risk of developing hepatocellular carcinoma in
patients with hepatitis C virus-related cirrhosis: a prospective
study. Cancer. 95:2539–2545. 2002. View Article : Google Scholar
|
|
30
|
Okan A, Cömlekçi A, Akpinar H, Okan I,
Yeşil S, Tankurt E and Simşek I: Serum concentration of
insulin-like growth factor-I and insulin-like growth factor binding
protein-3 in patients with chronic hepatitis. Scand J
Gastroenterol. 35:1212–1215. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Raslan H, Ezzat W, Ahmed M and Rasheed E:
Insulin growth-factor-1 and insulin-like growth factor binding
protein-3 in Egyptian patients with chronic hepatitis C. Arch Med
Sci. 3:46–51. 2007.
|
|
32
|
Su WW, Lee KT, Yeh YT, Soon MS, Wang CL,
Yu ML and Wang SN: Association of circulating insulin-like growth
factor 1 with hepatocellular carcinoma: one cross-sectional
correlation study. J Clin Lab Anal. 24:195–200. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Morali G, Shitrit AB, Eran M, Freier S,
Reinus C and Braverman D: Hepatic production of insulin-like growth
factors in normal and diseased liver. Hepatogastroenterology.
52:1511–1515. 2005.PubMed/NCBI
|
|
34
|
Stefano JT, Correa-Giannella ML, Ribeiro
CMF, Alves VAF, Massarollo PCB, Machado MCC and Giannella-Neto D:
Increased hepatic expression of insulin-like growth factor-I
receptor in chronic hepatitis C. World J Gastroenterol.
28:3821–3828. 2006.PubMed/NCBI
|
|
35
|
Huynh H, Chow PKH, Ooi LLP and Soo KC: A
possible role for insulin-like growth factor-binding protein-3
autocrine/paracrine loops in controlling hepatocellular carcinoma
cell proliferation. Cell Growth Differ. 13:115–122. 2002.
|
|
36
|
Clemmons DR: Insulin-like growth factor
binding proteins and their role in controlling IGF actions.
Cytokine Growth Factor Rev. 8:45–62. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kasprzak A, Adamek A, Przybyszewska W, et
al: Expression of IGF-1 and viral proteins (C, NS3, NS5A) in the
livers of patients with chronic HCV infection. Adv Clin Exp Med.
20:263–273. 2011.
|
|
38
|
Bedossa P and Poynard T: An algorithm for
the grading of activity in chronic hepatitis C. The METAVIR
Cooperative Study Group. Hepatology. 24:289–293. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kasprzak A, Adamek A, Biczysko W, et al:
Intracellular expression of the proliferative marker Ki-67 and
viral proteins (NS3, NS5A and C) in chronic, long lasting hepatitis
C virus (HCV) infection. Folia Histochem Cytobiol. 45:357–366.
2007.PubMed/NCBI
|
|
40
|
Hsu SM, Raine L and Fanger H: Use of
avidin-biotin-peroxidase complex (ABC) in immunoperoxidase
techniques: a comparison between ABC and unlabeled antibody (PAP)
procedures. J Histochem Cytochem. 29:577–580. 1981. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kaczmarek E and Strzelczyk R: From two to
three-dimensional visualisation of structures in light and confocal
microscopy - applications for biomedical studies. Current Issues on
Multidisciplinary Microscopy Research and Education. Mendez-Vilas A
and Labajos-Broncano L: (FORMATEX microscopy book series no II).
Formatex Research Centre; Badajoz: pp. 289–295. 2005
|
|
42
|
Mahdy KA, Ahmed HH, Mannaa F and
Abdel-Shaheed A: Clinical benefits of biochemical markers of bone
turnover in Egyptian children with chronic liver diseases. World J
Gastroenterol. 13:785–790. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Aimaretti G, Boschetti M, Corneli G, et
al: Normal age-dependent values of serum insulin growth factor-I:
results from a healthy Italian population. J Endocrinol Invest.
31:445–449. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Andreassen M, Nielsen K, Raymond I,
Kristensen LØ and Faber J: Characteristics and reference ranges of
insulin-like growth factor-I measured with a commercially available
immunoassay in 724 healthy adult Caucasians. Scand J Clin Lab
Invest. 69:880–885. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Rosario PW: Normal values of serum IGF-1
in adults: results from a Brazilian population. Arq Bras Endocrinol
Metabol. 54:477–481. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Holmes MD, Pollak MN and Hankinson SE:
Lifestyle correlates of plasma insulin-like growth factor I and
insulin-like growth factor binding protein 3 concentrations. Cancer
Epidemiol Biomarkers Prev. 11:862–867. 2002.
|
|
47
|
Colakošlu O, Taşkiran B, Colakoğlu G,
Kizildağ S, Ari Ozkan F and Unsal B: Serum insulin like growth
factor-1 (IGF-1) and insulin growth factor binding protein-3
(IGFBP-3) levels in liver cirrhosis. Turk J Gastroenterol.
18:245–249. 2007.
|
|
48
|
Plöckinger U, Krüger D, Bergk A, Weich V,
Wiedenmann B and Berg T: Hepatitis-C patients have reduced growth
hormone (GH) secretion which improves during long-term therapy with
pegylated interferon-alpha. Am J Gastroenterol. 102:2724–2731.
2007.PubMed/NCBI
|
|
49
|
Ichikawa T, Nakao K, Hamasaki K, et al:
Role of growth hormone, insulin-like growth factor 1 and
insulin-like growth factor-binding protein 3 in development on
non-alcoholic fatty liver disease. Hepatol Int. 1:287–294. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Arany E, Afford S, Strain AJ, Winwood PJ,
Arthur MJ and Hill DJ: Differential cellular synthesis of
insulin-like growth factor binding protein-1 (IGFBP-1) and IGFBP-3
within human liver. J Clin Endocrinol Metab. 79:1871–1876.
1994.PubMed/NCBI
|
|
51
|
Ross RJM, Chew SL, D’Souza Li L, et al:
Expression of IGF-I and IGF-binding protein genes in cirrhotic
liver. J Endocrinol. 149:209–216. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Mattera D, Capuano G, Colao A, Pivonello
R, Manguso F, Puzziello A and D’Agostino L: Increased IGF-I:IGFBP-3
ratio in patients with hepatocellular carcinoma. Clin Endocrinol
(Oxf). 59:699–706. 2003. View Article : Google Scholar : PubMed/NCBI
|
